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ABSTRACT: Introduction: Ryanodine receptor gene (RYR1)
mutations have been associated with central core disease
(CCD), multiminicore/minicore/multicore disease (MmD), and
susceptibility to malignant hyperthermia (MH). Methods: Pa-
tients with muscle symptoms in adulthood, who had features
compatible with CCD/MmD, underwent clinical, histological, and
genetic (RYR1 and SEPN1 genes) evaluations. Published
cases of CCD and MmD with adult onset were also reviewed.
Results: Eight patients fulfilled the criteria for further analysis.
Five RYR1 mutations, 4 of them unreported, were detected in 3
patients. Compound heterozygosity was proven in 1 case. Con-
clusions: To our knowledge, this is the only report of adult
onset associated with recessive RYR1 mutations and central
core/multiminicores on muscle biopsy. Although adult patients
with CCD, MmD, and minimally symptomatic MH with abnormal
muscle biopsy findings usually have a mild clinical course, dif-
ferential diagnosis and carrier screening is crucial for prevention
of potentially life-threatening reactions to general anesthesia.
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Central core disease (CCD; MIM #117000) is a
congenital myopathy in which type I skeletal mus-
cle ﬁbers exhibit amorphous areas with sarcomere
disorganization (cores) that lack mitochondria and
oxidative enzyme activity along the length of the
myoﬁber.1 CCD typically presents in infancy with
hypotonia and motor developmental delay. Ortho-
pedic complications are common, and susceptibil-
ity to malignant hyperthermia (MH) is a frequent
association,2 because CCD and MH are allelic con-
ditions. They both result predominantly from dom-
inant mutations in the skeletal muscle ryanodine
receptor gene (RYR1) that encodes the principal
sarcoplasmic reticulum calcium release channel.
Multiminicore/minicore/multicore disease (MmD;
MIM #117000, #602771, and #255320) can be distin-
guished from CCD based on histological ﬁndings and
by characteristic clinical features in some cases. Histo-
logically, type I and type II muscle ﬁbers are character-
ized by multiple cores that do not extend along the
entire length of the myoﬁber and short areas of sarco-
meric disorganization lacking mitochondria.1 MmD
was initially associated with recessive mutations in the
selenoprotein N1 gene (SEPN1),3 but there have
been increasing reports of recessive mutations in the
RYR1 gene being related to this entity,1,4–7 and
in some cases also with enhanced susceptibility to
MH.8–11 The onset of MmD is usually in infancy or
childhood with hypotonia or proximal weakness, and
only a limited number of cases have been reported
with onset in adult life.12–15 These are occasionally
associated with progressive muscle weakness and
respiratory or cardiac failure.
MH is a pharmacogenetic disorder in which sus-
ceptible individuals develop generalized muscle
contracture, followed by a hypermetabolic state due
to massive calcium release from the sarcoplasmic
reticulum when they are exposed to inhaled general
anesthetics or to the depolarizing muscle relaxant
succinylcholine. Abnormal muscle biopsy ﬁndings,
namely central cores and multiminicores, have been
described in MH,1,8,11 and a clear separation
between the CCD, MmD, and MH is not always possi-
ble. Thus, it is always advisable to consider the possi-
bility of MH whenever cores, multiminicores, or
both features are found on muscle biopsy.
We report a series of adult patients with muscle
symptoms, histological alterations compatible with
cores or multiminicores, and distinct genetic inher-
itance patterns. Our aim is to describe clinical, his-
tological, and genetic features of these patients
and also to review the previously reported cases in
the literature in order to improve the awareness of
adult-onset presentations of RYR1 mutations and,
subsequently, prevent life-threatening anesthetic
complications.
METHODS
We analyzed muscle biopsies performed in the
Neuropathology Laboratory of Santa Maria Hospi-
tal between 2002 and 2007 in order to select adult
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patients with nonspeciﬁc muscle complaints and
histopathological ﬁndings suggestive of CCD/
MmD. All biopsies performed during this period
in adults due to nonspeciﬁc muscle complaints
and without a ﬁnal diagnosis were reanalyzed (n ¼
309).
Muscle Histology Studies. Specimens were
obtained by an open muscle biopsy of the left del-
toid. They were frozen in isopentane cooled in liq-
uid nitrogen and stained using standard techni-
ques as described by Dubowitz and Sewry.16 In
addition, 6-mm sections were immunolabeled with
antibodies to desmin (mouse monoclonal; Dako)
and ab-crystallin (rabbit polyclonal; Chemicon).
Clinical Reassessment. Patients included in the
study were clinically re-evaluated, and data were
collected according to the following items: disease
onset (after 18 years of age); neuromuscular symp-
toms and laboratory ﬁndings of muscle weakness,
muscle atrophy, myalgia, and abnormal creatine ki-
nase (CK) levels; history of previous incidents
related to anesthetic procedures (malignant hyper-
thermia); and family history. All patients had a his-
tory of normal motor development. Signs or symp-
toms compatible with muscle involvement before
adulthood represented an exclusion criterion.
Literature Review. A literature review was per-
formed, using a PubMed search, to ﬁnd reports
written in English of patients who presented with
adult-onset CCD or MmD.
Genetic Analysis. Due to the exceptionally large
size of the RYR1 gene, mutation screening was per-
formed in a two-step strategy. All cases were ini-
tially subjected to direct genomic sequencing in
the three mutational hotspots (exons 1–17, 39–52,
and 92–105). The remaining RYR1 exons were
then sequenced in patients 2, 4, 5, 7, and 8.
Brieﬂy, genomic DNA was polymerase chain reac-
tion (PCR)-ampliﬁed using intronic M13-tailed pri-
mers. Amplicons were then sequenced (BigDye
Terminator Cycle Sequencing Kit, version 1.1;
Applied Biosystems, Foster City, California) and an-
alyzed on a genetic analyzer (ABI 3130xl; Applied
Biosystems). Sequence analysis was aided by Seq-
Scape v2.5 software (Applied Biosystems). Variant
nomenclature was according to the recommenda-
tions of the Human Genome Variation Society
(HGVS),17 using the reference cDNA sequence
ﬁled under GenBank Accession No. NM_000540.2.
For undocumented variants, a population screen
was performed on at least 150 anonymous control
samples. To further validate the pathogenicity of
unreported missense substitutions, phylogenetic
conservation analysis was performed using ryano-
dine receptor I sequences from several organisms
(list of sequence accession numbers in Supplemen-
tary Material) aligned by ClustalX software (version
2.0.12).18 In patients 5, 7, and 8, cDNA analysis
was conducted to further characterize novel var-
iants. RNA was extracted from muscle biopsies and
converted to cDNA used for PCR ampliﬁcation
and subsequent sequencing. Analysis of the SEPN1
gene was conducted in RYR1 mutation–negative
cases, namely 4, 5, 7, and 8, by direct genomic
sequencing of all exons and surrounding intronic
sequences and the selenocysteine insertion
sequence (SECIS) element located in the 30
untranslated region.
RESULTS
Clinical and Histological Findings. Tables 1 and 2
show the clinical and histological characteristics of
the patients included in this study. One patient
had proximal lower limb weakness, and the
remaining 7 patients complained of myalgia. Four
patients had elevated CK levels, between 421 and
619 IU/L (normal reference values: 32–294 IU/L).
Three patients had personal or family history of se-
rious adverse reactions to anesthetic procedures
(patients 1, 2, and 6), leading to death in 1 case
(patient 2). Two patients with identiﬁed mutations
had associated rheumatological complaints: gener-
alized arthralgia and fatigue in patient 1, and sys-
temic lupus erythematosis in patient 3.
Muscle biopsy studies showed nonspeciﬁc ﬁnd-
ings in all patients, namely variation in ﬁber size
and central nuclei. Type 1 ﬁber predominance was
present in 6 cases. Enzymatic reactions [nicotina-
mide adenine dinucleotide plus hydrogen
(NADH)-tetrazolium reductase, succinate dehydro-
genase (SDH), and cyclooxygenase (COX)] dis-
closed areas of absent activity characteristic of
cores and/or multiminicores (Fig. 1). Central
accumulation of periodic acid–Schiff (PAS)-stained
material was visualized in 6 cases (patients 1, 2, 3,
5, 6, and 7). In addition, desmin immunocyto-
chemical studies revealed antibody deposition colo-
calized with cores in 3 patients (patients 2, 3,
and 5).
Genetic Studies. Five heterozygous missense muta-
tions, four of which were previously unreported,
were detected in patients 1, 3, and 6 (Table 2).
In patient 1, two heterozygous mutations were
identiﬁed: c.6612C>G (p.His2204Gln) and
c.14228G>A (p.Gly4743Asp) in exons 40 and 98,
respectively. These novel mutations were not
detected in 300 control alleles, and ryanodine re-
ceptor 1 protein alignments suggested that the
alterations affected highly conserved amino acids
(Fig. 2A and B). Several family members of patient
1 were also studied (respective genotypes shown in
Fig. 3). The brother of patient 1 (individual II.3),
RYR1 Mutations in Adults with Core Lesions MUSCLE & NERVE July 2011 103
who shows clinical signs compatible with MmD, has
the same RYR1 genotype. The patient’s sons,
brother, and nephews, who harbor only one of the
mutations, are clinically asymptomatic. These results
are suggestive of an autosomal-recessive pattern of
inheritance for adult-onset MmD in this family.
Table 2. Histological and molecular data of patients..
Patient Muscle histology
RYR1 genotype*
SEPN1 genotypeVariant/pathogenicity Exon
Predicted
polypeptide change
1 Central cores, multiple
minicores, type I fiber
predominance
c.6612C>G / mut.
c.14228G>A / mut.
(only hotspots screened)
40
98
p.His2204Gln,
p.Gly4743Asp
Not performed
2 Central and eccentric
cores, type I fiber
predominance
No mut. detected — — Not performed
3 Central and peripheral
cores, predominantly
on type I fibers; type I
fiber predominance
c.479A>G / mut.19
(only hotspots screened)
6 p.Glu160Gly Not performed
4 Central cores, multiple
minicores, type I fiber
predominance
No mut. detected — — No mut. detected
5 Central and eccentric cores,
type I fiber predominance
No mut. detected — — No mut. detected
6 Multiminicores, type I fiber
predominance
c.10097G>A / mut.
c.11798A>G / mut.
(only hotspots screened)
6786 p.Arg3366His,
p.Tyr3933Cys
Not performed
7 Multiminicores,normal fiber
type differentiation
c.13477C>G / poly.
c.14505G>A / poly.
92100 p.Pro4493Ala— No mut. detected
8 Multiminicores, normal fiber
type differentiation
c.5360C>T / poly.,1,20
c.6178G>T / poly.1,20
3438 p.Pro1787Leu,
p.Gly2060Cys
No mut. detected
mut., mutation; poly., polymorphism.
*Variants detected in RYR1 coding sequence, reference sequence accession number NM_000540.2.
Table 1. Clinical and analytical data of patients.
Patient
Age*/
gender
Spine/joint
malformations
Muscle
weakness
Muscle
atrophy Myalgia
Malignant
hyperthermia
CK†
(IU/L) Additional features
1 43 y /F Generalized
arthralgia
— — þ Adverse reaction to
succinylcholine during
caesarean section
456 Fatigue, male
brother with MH
during surgery
and elevated CKs
2 48 y /F Pes planus — Calf
hypertrophy
þ — 601 AST and ALT
elevation,
son died
during surgical
procedure
3 55 y / F — — — þ Not submitted to
anesthetic procedures
before RYR1 study
264 SLE myopathic
EMG fatigue
4 58 y / M Pes cavus LL
proximal
— — — 270 Myopathic EMG
5 23y / M — — — þ — N —
6 59 y / M — — — þ Cardiorespiratory arrest
and rhabdomyolysis
during anesthetic
induction
619 Fatigue
7 49 y/ M — — — þ — 421 —
8 56 y/ M — — — þ — N —
y, years; m, male; F, female; LL, lower limbs; þ, presence; , absence; MH, malignant hyperthermia; N, normal; EMG, electromyogram; AST, aspartate
aminotransferase; ALT, alanine transaminase; SLE, systemic lupus erythematosus.
*At first symptoms.
†Highest value during follow-up.
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Patient 3 had the heterozygous mutation
c.479A>G (p.Glu160Gly) in exon 6. This variation
was previously reported to be associated with an
MH/CCD phenotype.19
In patient 6, two heterozygous missense variants
were detected: c.10097G>A (p.Arg3366His) in
exon 67 and c.11798A>G (p.Tyr3933Cys) in exon
86. Both variants were considered pathogenic,
because they were not detected in control samples
and predictably altered conserved residues (Fig. 2C
and D). Because no relatives were available for
study, mutation allelism could not be conﬁrmed or
excluded in this case.
In the remaining patients (2, 4, 5, 7, and 8),
the RYR1 gene was fully sequenced, but no causa-
tive mutations were identiﬁed. Seven RYR1 poly-
morphisms were also detected in this study. These
included two previously reported missense poly-
morphisms c.5360C>T and c.6178G>T1,20 in
patient 8, and a novel missense change
c.13477C>G (p.Pro4493Ala) in patient 7. The lat-
ter was also detected in heterozygosity in 1 control
sample (1 of 300 alleles) and affects a non-con-
served amino acid. The remainder were a silent
change (c.14505G>A) in exon 100 and three
intronic base changes: c.3765þ130A>G (intron
27), c.5548-76G>A (intron 34), and c.10627-
45A>T (intron 71). These four variants were fur-
ther analyzed at the cDNA level, but none
appeared to inﬂuence mRNA splicing.
The SEPN1 gene was also screened for patho-
genic changes in patients 4, 5, 7, and 8, but no
causative mutations were detected.
Late-Onset CCD/MmD Literature Review. From the
literature review, cases were selected for compara-
tive evaluation. HyperCKemia13,15,21–23 and proxi-
mal muscle weakness12,13,23,24 were the most fre-
quently reported features. Myalgia was described
less often.14,21,23 One case was associated with scoli-
osis,24 and another was characterized by an axial
myopathy with prominent involvement of the spine
extensors.22 The most consistent ﬁndings in mus-
cle biopsies were type I ﬁber predominance,
increased number of central nuclei, and the ab-
sence of enzymatic staining on SDH and NADH–
tetrazolium reductase. Labeling of desmin in the
core region was the most frequent immunohisto-
chemical ﬁnding. A detailed description of these
patients is presented in Table 3.
DISCUSSION
In this work we have presented a clinical, histologi-
cal, and genetic report on patients in whom cores
or multiminicores were detected on muscle biop-
sies performed due to muscle complaints appear-
ing during adulthood. Although most patients did
not meet all the diagnostic criteria of adult-onset
CCD or MmD, muscle complaints were considered
signiﬁcant enough to justify a muscle biopsy, where
central cores or multiminicores were found. These
ﬁndings oriented genetic studies and helped pre-
vent additional anesthetic complications.
Adult patients with CCD/MmD/MH and/or
abnormal muscle biopsy ﬁndings usually have mild
phenotypes (myalgia, mild CK elevation, and dis-
crete proximal and/or axial weakness), but we also
found reports of progressive disease with respira-
tory failure13 and hypertrophic cardiomyopathy.12
The association with joint deformities in 2 of our
patients was also reported in the literature. When
axial muscles are involved, scoliosis is a common
ﬁnding.22,23,25 Unexplained joint deformities in
patients with muscle complaints should therefore
raise the suspicion of CCD or MmD.
FIGURE 1. Skeletal muscle sections of the 8 patients studied,
stained with succinate dehydrogenase, revealing core and/or
multiminicore lesions. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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Rheumatological disorders, as found in our
patients 1 and 3, have also been described previ-
ously in association with these myopathies,26
although the physiopathological relation between
them remains unexplained. In our series, muscle
pain (myalgia or cramps) was one of the most fre-
quent clinical signs and, in some cases, the only
complaint pointing toward a muscle disorder.
Two patients had both central cores and multi-
minicores on the biopsy, and one of these had
RYR1 mutations. A continuum between the histo-
pathological appearance of CCD and MmD related
to RYR1 mutations has been suggested,11,15 with
evolution over time, as observed on consecutive
muscle biopsies of the same patient.7,28
The histological features found in this study are
similar to those described in the literature (see
Table 2). The scarcity of clinical ﬁndings contrasted
with the marked morphological changes, namely
type 1 ﬁber predominance, central nuclei, variabili-
ty in ﬁber size, and cores and multiminicores on
SDH and NADH staining. Immunohistochemistry
with desmin can be useful to show the presence of
cores, as was demonstrated by the colocalization of
cores and desmin accumulation. The disturbance
of desmin may be related to the ultrastructural
appearance of misaligned myoﬁbrils, because
desmin links the myoﬁbrils at the Z-line.27,28
In our group of patients, ﬁve missense muta-
tions were identiﬁed in the RYR1 gene. We could
not ﬁnd a clear clinical or histological distinction
between patients with identiﬁed RYR1 mutations
and patients with no causative changes in this
gene. Four of these mutations were not previously
reported: c.6612C>G (p.His2204Gln), c.10097G>A
(p.Arg3366His), c.11798A>G (p.Tyr3933Cys), and
c.14228G>A (p.Gly4743Asp). None of these var-
iants were detected in control samples, and all pre-
dictably affected conserved residues in the ryano-
dine receptor 1 (RyR1) protein. Only mutation
p.Gly4743Asp, found in patient 1, is located in the
principal CCD mutational hotspot (C-terminal resi-
dues 4647–4914).25 It has been suggested that
FIGURE 2. New mutations identified in patient 1 (A, B) and patient 6 (C, D). In the lower panes are the partial sequence alignments
of ryanodine receptor type 1 sequences from several organisms (accession numbers in Supplementary Material). Affected residues
are indicated by arrows. Other annotations are as follows: (*) fully conserved residue; (:) partially conserved residue within strong
amino acid cluster; (l) partially conserved residue within weak amino acid cluster. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
FIGURE 3. Pedigree of patient 1’s family (arrow indicates
patient 1). RYR1 genotypes are indicated below each of the 7
individuals who were studied.
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mutations located in the C-terminal region are
associated with speciﬁc clinical ﬁndings, such as in-
fantile hypotonia, delayed motor development,
and limb muscle weakness.29 In contrast, the ma-
jority of CCD patients with at least one mutation
located outside this region present milder muscu-
loskeletal abnormalities, such as joint contractures
and scoliosis.29 Our work corroborates these obser-
vations, considering the mutation spectrum in this
particular cohort with mild clinical presentation
and late onset. The second mutation detected in
patient 1 (p.His2204Gln) is located in hotspot 2,
more precisely between amino acids 1924 and
2446, a region found to be critical for excitation–
contraction (E-C) coupling.30 Two mutations were
also detected in patient 6: p.Arg3366His, in the vi-
cinity of the previously reported mutation
p.Lys3367Arg identiﬁed in a Japanese patient with
MH and CCD,31 and p.Tyr3933Cys. The latter
affects a residue located within the RyR and IP3R
homology–associated domain. This domain is found
in ryanodine receptors and inositol 1,4,5-trisphos-
phate receptors, which comprise a superfamily of
homotetrameric ligand–gated intracellular Ca2þ
channels.32
It was perhaps unexpected to ﬁnd that 2 of the
3 characterized patients (1 and 6) each had two
missense mutations. In the ﬁrst case, family studies
were conducted, and results are compatible with
an autosomal-recessive pattern of inheritance. The
mutations were seen to be allelic, and only the 2
individuals with both alterations had clear clinical
signs of the disease. In terms of muscle histology,
patient 1 presented both central cores and multi-
minicores. MH susceptibility was not conﬁrmed
experimentally, but she experienced an adverse
Table 3. Reported cases of central core and multiminicore disease with adult presentation..
Age/
gender Myalgia
Spine/joint
malformation
Muscle
weakness MH CK*(IU/L)
Additional
features Muscle, histology
RYR1
genotype Reference
46 y/ M þ — Neck flexors,
UL proximal,
LL proximal
— 209 Myopathic EMG Marked type
1 fiber
predominance,
central cores
on oxidative
staining.
Not reported 23
2 9 y / M — — Generalized,
predominantly
proximal
— N High-arched
palate,
biventricular
enlargement,
myopathic
EMG
Marked type 1
fiber
predominance,
multiminicores
Not reported 12
43 y / F — — Facial, truncal
diaphragm, UL
proximal, LL
proximal
— 500 Fatigue,
cardiorespiratory
failure
Selective type
I fiber atrophy,
multiminicores
Not reported 13
46 y / M — — — — Varying
elevation
Fatigue,
myopathic
EMG
Multiminicores,
slight type
1 fiber
predominance,
central cores
c.1201C>T
(exon 12),
p.Arg401Cys†
15
47 y / F þ — — — N Exertional fatigue,
myopathic EMG
Type I fiber
predominance,
multiminicores
and central
cores
Not reported 14
45 y / M — Scoliosis UL proximal — N Severe restriction
of pulmonary
function
Single and
central cores
Not reported 24
58 y / M þ — LL asymmetric — Mildelevation — Central cores Not reported 21
77 y / M — Axial
myopathy
Prominent
involvement
of spine
extensors
— 499 Myopathic EMG
(in the lumbar
and lower
thoracic
paraspinal
muscles)
Marked type
1 fiber
predominance,
central and
eccentric
cores
c.119G>T
(exon 2),
p.Gly40Val
22
y, years; M, male; F, female; LL, lower limbs; UL, upper limbs; þ, presence; -, absence; EMG, electromyogram; N, normal; MH, malignant hyperthermia.
*Highest value during follow-up.
†RYR1 partially sequenced (34 exons).
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reaction to succinylcholine during an anesthetic
intervention. CCD and MmD were initially thought
to be inherited in an autosomal-dominant manner.
However, there have been reports of at least 18
families with compound heterozygosity, as proven
by haplotyping and/or segregation analysis.4,7,30,33–
36 Nevertheless, the majority of the previously
reported RYR1 recessive cases had a neonatal or
childhood onset. Our report adds some more com-
plexity to this picture and widens the phenotypic
variability. Accordingly, because RYR1 is a large
gene, and mutation screening is often limited to
the hotspot regions, it was previously recognized
that autosomal-recessive cases are probably under-
estimated in the literature.35
Although the genetic cause of the phenotype
in some patients remains to be established, either
due to RYR1 mutations, which are undetectable by
routine methods, or to defects in other genes, our
ﬁndings support the idea that RYR1 mutation
screening should be considered in cases with
adult-onset, mild muscle symptoms and histological
ﬁndings compatible with CCD or MmD. Consider-
ing these inclusion criteria, the detection of RYR1
mutations in 3 of our 8 patients (38%) seems sufﬁ-
ciently relevant to validate our study approach.
The ﬁrst two authors (S.T.D. and J.O.) contributed equally to this
work. We thank Dr. Jose´ Pedro Vieira for helpful manuscript
review.
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